Patent Application No.: 09/523,647

Filed: March 10, 2000

Attorney Docket No. 032931/0227

Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in

the application:

Claims 1-7 (Cancelled)

Claim 8. (Currently amended) A vaccine vector comprising a nucleic acid sequence

which encodes:

(a) — SEQ-ID-No: 2; or

(b) a fragment comprising at least 12 consecutive amino acids from SEQ ID No:2,

wherein the fragment defines an immunogenic epitope of Chlamydia;

A vaccine vector comprising an isolated nucleic acid molecule which encodes SEQ

ID No: 2, wherein the nucleic acid molecule is operably linked to a promoter

functional in a mammalian cell.

Claim 9. (Currently amended) The vaccine vector of claim 39 8 further comprising

another nucleic acid encoding an additional polypeptide which enhances the immune

response to the polypeptide having SEQ ID No: 2, wherein the additional polypeptide

is a Chlamydia polypeptide.

Claim 10 (Cancelled)

Claim 11. (Previously presented): A vaccine comprising the vaccine vector according

to claim 8 and a pharmaceutically acceptable carrier.

Claims 12-39 (Canceled)

Claim 40 (Previously presented): The vaccine of claim 8 wherein the promoter is a

viral promoter.

Patent Application No.: 09/523,647

Filed: March 10, 2000

Attorney Docket No. 032931/0227

Page 3

Claim 41 (Previously presented): The vaccine of claim 9 wherein the promoter is a viral promoter.

Claim 42 (Previously presented): The vaccine of claim 11 wherein the promoter is a viral promoter.

Claim 43 (Canceled)

Claim 44 (Previously presented): The vaccine vector of claim 8 wherein the promoter is cytomegalovirus (CMV) promoter.

Claim 45 (Previously presented): The vaccine of claim 9 wherein the promoter is cytomegalovirus (CMV) promoter.

Claim 46 (Previously presented): The vaccine of claim 11 wherein the promoter is cytomegalovirus (CMV) promoter.

Claim 47 (Canceled)

Claim 48 (New): The vaccine vector of claim 8 wherein the nucleotide sequence of the nucleic acid molecule which encodes SEQ ID No:2 is SEQ ID No:1.

Claim 49 (New): The vaccine vector of claim 9 wherein the nucleotide sequence of the nucleic acid molecule which encodes SEQ ID No:2 is SEQ ID No:1.

Claim 50 (New): The vaccine vector of claim 11 wherein the nucleotide sequence of the nucleic acid molecule which encodes SEQ ID No:2 is SEQ ID No:1.

Claim 51 (New): The vaccine vector of claim 40 wherein the nucleotide sequence of the nucleic acid molecule which encodes SEQ ID No:2 is SEQ ID No:1.

Patent Application No.: 09/523,647

Filed: March 10, 2000

Attorney Docket No. 032931/0227

Page 4

Claim 52 (New): The vaccine vector of claim 44 wherein the nucleotide sequence of the nucleic acid molecule which encodes SEQ ID No:2 is SEQ ID No:1.